- Home
- LOAN vs BRNS Comparison
LOAN vs BRNS Comparison
Compare LOAN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- BRNS
- Stock Information
- Founded
- LOAN 1989
- BRNS 2016
- Country
- LOAN United States
- BRNS United Kingdom
- Employees
- LOAN N/A
- BRNS N/A
- Industry
- LOAN Real Estate Investment Trusts
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- BRNS Health Care
- Exchange
- LOAN Nasdaq
- BRNS Nasdaq
- Market Cap
- LOAN 64.4M
- BRNS 52.0M
- IPO Year
- LOAN 1999
- BRNS 2021
- Fundamental
- Price
- LOAN $5.32
- BRNS $0.97
- Analyst Decision
- LOAN
- BRNS Strong Buy
- Analyst Count
- LOAN 0
- BRNS 2
- Target Price
- LOAN N/A
- BRNS $4.00
- AVG Volume (30 Days)
- LOAN 13.3K
- BRNS 31.7K
- Earning Date
- LOAN 10-23-2024
- BRNS 11-06-2024
- Dividend Yield
- LOAN 8.65%
- BRNS N/A
- EPS Growth
- LOAN 6.53
- BRNS N/A
- EPS
- LOAN 0.49
- BRNS N/A
- Revenue
- LOAN $7,394,068.00
- BRNS $14,969,000.00
- Revenue This Year
- LOAN N/A
- BRNS N/A
- Revenue Next Year
- LOAN N/A
- BRNS N/A
- P/E Ratio
- LOAN $10.86
- BRNS N/A
- Revenue Growth
- LOAN 5.79
- BRNS 106.21
- 52 Week Low
- LOAN $4.27
- BRNS $0.88
- 52 Week High
- LOAN $5.90
- BRNS $4.16
- Technical
- Relative Strength Index (RSI)
- LOAN 43.98
- BRNS 30.37
- Support Level
- LOAN $5.32
- BRNS $1.28
- Resistance Level
- LOAN $5.50
- BRNS $1.52
- Average True Range (ATR)
- LOAN 0.08
- BRNS 0.13
- MACD
- LOAN -0.01
- BRNS -0.04
- Stochastic Oscillator
- LOAN 15.63
- BRNS 14.09
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.